Clinical Trial

R. Officinalis as Pulpotomy Agent in Permanent Teeth With Irreversible Pulpitis

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This study evaluates and compares the clinical and radiographic outcomes of Rosmarinus officinalis and Mineral Trioxide Aggregate (MTA) when used as pulpotomy medicaments in vital mature permanent teeth with irreversible pulpitis. The aim is to determine the effectiveness of both materials in terms of pain reduction and periapical healing. While MTA is considered a gold standard, it has limitations such as high cost, long setting time, and potential discoloration. Therefore, this study investigates Rosmarinus officinalis as a natural, cost-effective alternative with comparable therapeutic potential. This study also provide an alternative to RCT in teeth with irreversible pulpitis
Trial Details
NCT Number NCT07610057
Lead Sponsor University of Health Sciences Lahore
Conditions Irreversible Pulpitis, Pulpotomy, MTA Vital Tooth Pulpotomy
Enrollment 100 participants
Start Date 2026-06-01
Primary Completion 2026-12-01 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-27